Germany· DE-A57-8f3ed80585a94cad

Ifo-Cell

A ifosfamide product containing ifosfamide, registered in Germany by Stadapharm Gmbh. The same ATC class is registered in 15 of our 19 countries.

ATC L01AA06

Checked against EMA Article 57 (European Union) on September 30, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ifosfamideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Ifosfamide is registered in 15 of 19 countries.

Countries holding a registration under ATC L01AA06 (ifosfamide), each read from that country’s own register.

This record: Germany, from EMA Article 57 (European Union)
9 of them publish a price we can compare per daily dose

Search ifosfamide products by name

Ifosfamide · ATC L01AA06

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ifosfamide costs, country by country.

Normalised to the WHO defined daily dose (0.7 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Ifosfamide · price per daily dose (0.7 g)

USD · FX 28 Sept 2026

CH Switzerland$52.67

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

EMA Article 57 (European Union)

Active substance: Ifosfamide
Manufacturer: Stadapharm Gmbh
Country: Germany (DE)
ATC code: L01AA06
ATC class: Ifosfamide
Defined daily dose: 0.7 g, P
Reimbursed: Not published by this register
Source register: EMA Article 57 (European Union)
Last checked: September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

514 interactions on record for ifosfamide.

Graded by severity as the source publishes them — 41 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check ifosfamide against other medicines How interaction checks work

Ifosfamide · interactions on record

514 records

41 severe
385 moderate
16 minor
72 info

Most severe, free to view

Nalidixic acidJ01MB02severe
CidofovirJ05AB12severe
ThiotepaL01AC01severe
CladribineL01BB04severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ifosfamide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ifosfamide products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

Austria · Holoxan
Belgium · Holoxan
Bulgaria · Холоксан
Czechia · Holoxan
Denmark · Holoxan
Estonia · Holoxan
Spain · Tronoxal
Finland · Holoxan
France · Holoxan, Ifosfamide Eg
United Kingdom (Northern Ireland) · Ifosfamide Baxter Healthcare
Greece · Holoxan
Croatia · Holoxan
Hungary · Holoxan
Ireland · Mitoxana
Iceland · Holoxan
Italy · Holoxan
Lithuania · Holoxan
Luxembourg · Holoxan
Latvia · Holoxan
Malta · Mitoxana
Netherlands · Holoxan
Norway · Holoxan
Poland · Holoxan
Portugal · Holoxan
Romania · Holoxan
Sweden · Holoxan
Slovenia · Holoxan
Slovakia · Holoxan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/8facefad-9d60-458f-a59e-3208c67c2284
GET /v1/drugs/8facefad-9d60-458f-a59e-3208c67c2284?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Intravenous Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Ifosfamide",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}

API reference MCP server Plans

See everything about ifosfamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console